Conference abstractPublished 26 Jun 2017
Impact of L-carnitine pretreatment on intravenous iron administration-induced oxidative stress and inflammatory response in patients with CKD
The Nazareth Hospital-EMMS, Israel Bar-Ilan University, Israel HaEmek Hospital, Israel Rambam Health Care Campus, Israel Technion, Israel
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Anemia is a common problem in CKD patients. It is attributed to decreased erythropoietin (EPO) production, low iron stores, and the chronic inflammatory milieu. Therefore, therapy includes not only recombinant EPO, but also irons replenishment. However, the latter induces oxidative stress as well as inflammation. Randomized, controlled studies suggested that L-carnitine supplementation might have positive effects on the response to EPO in long term hemodialysis patients. However, there is no evidence whether this approach is also beneficial in earlier-stage CKD patients. Thus, the present study examined whether L-carnitine prevents IVIR-induced oxidative stress and whether it improves response to EPO. Aims: Our hypothesis is that: 1. Intravenous administration of iron (IVIR) to CKD patients at early stages of the diseases (Stage 2-4) provokes oxidative stress and inflammation; 2. Prophylactic L-carnitine supplementation could prevent the IVIR-induced oxidative stress and inflammatory responses in these patients. Methods: The current study included 32 anemic CKD patients (stages 2-4) that were divided into 2 subgroups: Group of 16 patients was given a weekly IVIR (Sodium ferric gluconate, [125 mg/100 ml] for 12 weeks. Group 2: Sixteen patients received the same IVIR regimen but also carnitine (20 mg/kg, IV) was administered weekly 30 min prior to IVIR administration through the whole treatment period. Weekly blood samples were drawn before and after each IVIR for Hb, C-reactive protein (CRP), advanced oxidative protein products (AOPP), TBARS and neutrophil gelatinase-associated lipocalin (NGAL), in addition to routine complete blood count and biochemical analyses. Results: Combined administration of IVIR and carnitine increased Hb more profoundly (+8%) than those treated with IVIR alone (+13%). While IVIR alone induced oxidative and inflammatory responses, patients who received carnitine did not exhibit these adverse effects, as was evident by abolishing IVIR-induced elevation in CRP, NGAL, AOPP, and TBARS. Conclusion: Our finding demonstrated that co-administration of carnitine with IVIR preferentially attenuates the adverse consequences of IVIR, suggests a role for Carnitine therapy in these patients.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Zaher Armaly”
- BylineArticles whose byline prints “Kamal Hassan”
- BylineArticles whose byline prints “Nayef Habashi”
- BylineArticles whose byline prints “Rawi Ramadan”
- BylineArticles whose byline prints “Zaid Abassi”
